A phase I dose escalation, safety and pharmacokinetic (PK) study of AZD5312 (IONIS-ARRx), a first-in-class Generation 2.5 antisense oligonucleotide targeting the androgen receptor (AR)
Chowdhury, S., Burris, H.A., Patel, M., Infante, J.R., Jones, S.F., Voskoboynik, M., Parry, K., Elvin, P., Coleman, T., Gardner, H., Lyne, P.D., Arkenau, H.T.Volume:
69
Language:
english
Journal:
European Journal of Cancer
DOI:
10.1016/s0959-8049(16)33031-3
Date:
December, 2016
File:
PDF, 50 KB
english, 2016
File converter
More search results
More benefits 
